Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Zymeworks Inc. (ZYME) since 2022 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Zymeworks Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1937653.
Total stock buying since 2022: $74,770,990.
Total stock sales since 2022: $1,822,160.
Total stock option exercises since 2022: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 2,697,949 | $33,288,917 | 89,601 | $1,337,203 | 171,498 | $0 |
| 2024 | 0 | $0 | 39,697 | $428,195 | 75,332 | $0 |
| 2023 | 4,842,600 | $41,482,073 | 3,863 | $31,387 | 6,758 | $0 |
| 2022 | 0 | $0 | 3,362 | $25,375 | 7,435 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 55,421 | $635,594 | 0 | $0 | 0 | $0 |
| 2025-04 | 568,939 | $6,526,067 | 0 | $0 | 0 | $0 |
| 2025-03 | 1,539,387 | $18,910,020 | 0 | $0 | 0 | $0 |
| 2025-01 | 534,202 | $7,217,236 | 89,601 | $1,337,203 | 171,498 | $0 |
| 2024-01 | 0 | $0 | 39,697 | $428,195 | 75,332 | $0 |
| 2023-12 | 0 | $0 | 886 | $8,089 | 1,550 | $0 |
| 2023-06 | 3,350,000 | $27,201,999 | 0 | $0 | 0 | $0 |
| 2023-03 | 200,000 | $1,600,000 | 2,977 | $23,298 | 5,208 | $0 |
| 2023-01 | 1,292,600 | $12,680,074 | 0 | $0 | 0 | $0 |
| 2022-12 | 0 | $0 | 887 | $5,330 | 1,550 | $0 |
| 2022-11 | 0 | $0 | 2,475 | $20,045 | 5,885 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-19 | Nodelman Oleg | Buy | 5,919 | 11.78 | 69,737 |
| 2025-05-15 | Nodelman Oleg | Buy | 49,502 | 11.43 | 565,857 |
| 2025-04-17 | Nodelman Oleg | Buy | 54,760 | 11.52 | 630,835 |
| 2025-04-16 | Nodelman Oleg | Buy | 73,953 | 11.16 | 825,611 |
| 2025-04-04 | Nodelman Oleg | Buy | 196,438 | 11.17 | 2,193,819 |
| 2025-04-03 | Nodelman Oleg | Buy | 120,770 | 11.84 | 1,430,158 |
| 2025-04-02 | Nodelman Oleg | Buy | 74,360 | 11.85 | 881,017 |
| 2025-04-01 | Nodelman Oleg | Buy | 48,658 | 11.60 | 564,627 |
| 2025-03-31 | Nodelman Oleg | Buy | 4,397 | 11.75 | 51,660 |
| 2025-03-26 | Nodelman Oleg | Buy | 43,848 | 12.24 | 536,874 |
| 2025-03-25 | Nodelman Oleg | Buy | 53,501 | 12.90 | 690,430 |
| 2025-03-24 | Nodelman Oleg | Buy | 22,689 | 13.08 | 296,840 |
| 2025-03-21 | Nodelman Oleg | Buy | 31,033 | 12.78 | 396,508 |
| 2025-03-20 | Nodelman Oleg | Buy | 73,476 | 12.93 | 949,897 |
| 2025-03-19 | Nodelman Oleg | Buy | 58,306 | 12.64 | 737,221 |
| 2025-03-18 | Nodelman Oleg | Buy | 113,880 | 12.65 | 1,440,809 |
| 2025-03-17 | Nodelman Oleg | Buy | 56,277 | 12.23 | 688,492 |
| 2025-03-13 | Nodelman Oleg | Buy | 468,356 | 12.48 | 5,847,424 |
| 2025-03-12 | Nodelman Oleg | Buy | 292,934 | 12.25 | 3,587,855 |
| 2025-03-11 | Nodelman Oleg | Buy | 320,690 | 11.49 | 3,686,010 |
| 2025-01-17 | Ecor1 Capital, Llc | Buy | 19,748 | 13.88 | 274,003 |
| 2025-01-16 | Ecor1 Capital, Llc | Buy | 121,681 | 13.88 | 1,689,540 |
| 2025-01-15 | Ecor1 Capital, Llc | Buy | 39,029 | 14.01 | 546,679 |
| 2025-01-14 | Ecor1 Capital, Llc | Buy | 54,500 | 13.56 | 739,292 |
| 2025-01-13 | Ecor1 Capital, Llc | Buy | 74,125 | 13.39 | 992,904 |
| 2025-01-10 | Ecor1 Capital, Llc | Buy | 204,098 | 13.13 | 2,678,990 |
| 2025-01-08 | Ecor1 Capital, Llc | Buy | 21,021 | 14.07 | 295,828 |
| 2025-01-06 | Moore Paul Andrew (Chief Scientific Officer) | Sale | 21,200 | 14.92 | 316,388 |
| 2025-01-06 | Moore Paul Andrew (Chief Scientific Officer) | Option Ex | 37,166 | .00 | 0 |
| 2025-01-06 | Smith Jeffrey T L (EVP & Chief Medical Officer) | Sale | 11,110 | 14.92 | 165,805 |
| 2025-01-06 | Smith Jeffrey T L (EVP & Chief Medical Officer) | Option Ex | 20,000 | .00 | 0 |
| 2025-01-06 | Galbraith Kenneth (Chair & CEO) | Sale | 57,291 | 14.92 | 855,010 |
| 2025-01-06 | Galbraith Kenneth (Chair & CEO) | Option Ex | 114,332 | .00 | 0 |
| 2024-01-08 | Moore Paul Andrew (Chief Scientific Officer) | Sale | 2,339 | 11.22 | 26,234 |
| 2024-01-08 | Astle Christopher (SVP & Chief Financial Officer) | Sale | 1,431 | 11.22 | 16,050 |
| 2024-01-08 | Galbraith Kenneth (Chair & CEO) | Sale | 5,706 | 11.22 | 63,998 |
| 2024-01-05 | Moore Paul Andrew (Chief Scientific Officer) | Sale | 7,460 | 10.65 | 79,463 |
| 2024-01-05 | Moore Paul Andrew (Chief Scientific Officer) | Option Ex | 17,166 | .00 | 0 |
| 2024-01-05 | Astle Christopher (SVP & Chief Financial Officer) | Sale | 4,563 | 10.65 | 48,605 |
| 2024-01-05 | Astle Christopher (SVP & Chief Financial Officer) | Option Ex | 10,500 | .00 | 0 |
| 2024-01-05 | Galbraith Kenneth (Chair & CEO) | Sale | 18,198 | 10.65 | 193,845 |
| 2024-01-05 | Galbraith Kenneth (Chair & CEO) | Option Ex | 47,666 | .00 | 0 |
| 2023-12-11 | Astle Christopher (SVP & Chief Financial Officer) | Sale | 886 | 9.13 | 8,089 |
| 2023-12-11 | Astle Christopher (SVP & Chief Financial Officer) | Option Ex | 1,550 | .00 | 0 |
| 2023-06-16 | Ecor1 Capital, Llc | Buy | 3,350,000 | 8.12 | 27,201,999 |
| 2023-03-28 | Ecor1 Capital, Llc | Buy | 200,000 | 8.00 | 1,600,000 |
| 2023-03-10 | Klompas Neil A (President & COO) | Sale | 2,977 | 7.83 | 23,298 |
| 2023-03-10 | Klompas Neil A (President & COO) | Option Ex | 5,208 | .00 | 0 |
| 2023-01-20 | Ecor1 Capital, Llc | Buy | 163,400 | 9.88 | 1,615,045 |
| 2023-01-19 | Ecor1 Capital, Llc | Buy | 144,100 | 9.49 | 1,367,653 |
| 2023-01-18 | Ecor1 Capital, Llc | Buy | 203,000 | 9.99 | 2,028,984 |
| 2023-01-17 | Ecor1 Capital, Llc | Buy | 440,000 | 9.80 | 4,313,760 |
| 2023-01-13 | Ecor1 Capital, Llc | Buy | 342,100 | 9.81 | 3,354,632 |
| 2022-12-12 | Astle Christopher (SVP & Chief Financial Officer) | Sale | 887 | 6.01 | 5,330 |
| 2022-12-12 | Astle Christopher (SVP & Chief Financial Officer) | Option Ex | 1,550 | .00 | 0 |
| 2022-11-10 | Josephson Neil (Chief Medical Officer) | Sale | 2,475 | 8.10 | 20,045 |
| 2022-11-10 | Josephson Neil (Chief Medical Officer) | Option Ex | 5,885 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of ZYME listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Zymeworks Inc. (symbol ZYME, CIK number 1937653) see the Securities and Exchange Commission (SEC) website.